Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHA:688393)
China · Delayed Price · Currency is CNY 25.94
+0.93 (3.72%)
At close: Mar 6, 2026
SHA:688393 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 347.27 | 464.8 | 490.94 | 504.62 | 437.44 |
Other Revenue | - | 5.99 | 6.35 | 2.76 | 1.55 |
| 347.27 | 470.79 | 497.29 | 507.38 | 438.99 | |
Revenue Growth (YoY) | -26.24% | -5.33% | -1.99% | 15.58% | 16.93% |
Cost of Revenue | - | 159.61 | 161.87 | 148.97 | 98.6 |
Gross Profit | 347.27 | 311.18 | 335.42 | 358.41 | 340.39 |
Selling, General & Admin | - | 262.83 | 258.79 | 260.14 | 232.02 |
Research & Development | - | 45.47 | 62.69 | 67.39 | 45.9 |
Other Operating Expenses | 399.18 | 1.78 | 1.9 | 4.04 | 1.97 |
Operating Expenses | 399.18 | 315.75 | 327.88 | 336.92 | 281.59 |
Operating Income | -51.91 | -4.56 | 7.54 | 21.49 | 58.8 |
Interest Expense | - | -0.65 | -0.81 | -1.36 | -0.38 |
Interest & Investment Income | - | 11.99 | 8.8 | 7.69 | 19.12 |
Earnings From Equity Investments | - | 0 | 0 | -0 | - |
Currency Exchange Gain (Loss) | - | -0.02 | -0.08 | 0.14 | -0.06 |
Other Non Operating Income (Expenses) | -4.12 | -0.25 | -0.31 | -0.28 | -0.38 |
EBT Excluding Unusual Items | -56.03 | 6.52 | 15.14 | 27.68 | 77.09 |
Impairment of Goodwill | - | - | -3.06 | - | - |
Gain (Loss) on Sale of Investments | - | 2.53 | 5.14 | -3.14 | 6.12 |
Gain (Loss) on Sale of Assets | - | 0.16 | -0.64 | 0.15 | -0.61 |
Asset Writedown | - | -3.69 | - | - | - |
Other Unusual Items | - | 3.92 | 0.27 | 4.11 | 6.12 |
Pretax Income | -56.03 | 9.43 | 16.85 | 28.79 | 88.72 |
Income Tax Expense | -11.06 | -5.47 | -4.17 | -0.54 | 13.44 |
Earnings From Continuing Operations | -44.97 | 14.9 | 21.02 | 29.33 | 75.28 |
Minority Interest in Earnings | - | 6.39 | 19.04 | 13.36 | 4.49 |
Net Income | -44.97 | 21.29 | 40.06 | 42.69 | 79.78 |
Net Income to Common | -44.97 | 21.29 | 40.06 | 42.69 | 79.78 |
Net Income Growth | - | -46.85% | -6.18% | -46.48% | -5.87% |
Shares Outstanding (Basic) | 94 | 93 | 93 | 93 | 94 |
Shares Outstanding (Diluted) | 94 | 93 | 95 | 95 | 94 |
Shares Change (YoY) | 1.21% | -2.94% | 0.53% | 1.09% | 20.71% |
EPS (Basic) | -0.48 | 0.23 | 0.43 | 0.46 | 0.85 |
EPS (Diluted) | -0.48 | 0.23 | 0.42 | 0.45 | 0.85 |
EPS Growth | - | -45.24% | -6.67% | -47.06% | -22.02% |
Free Cash Flow | - | -20.1 | -20.62 | -62.45 | -83.73 |
Free Cash Flow Per Share | - | -0.22 | -0.22 | -0.66 | -0.89 |
Dividend Per Share | - | 0.100 | 0.150 | 0.140 | 0.270 |
Dividend Growth | - | -33.33% | 7.14% | -48.15% | -3.57% |
Gross Margin | 100.00% | 66.10% | 67.45% | 70.64% | 77.54% |
Operating Margin | -14.95% | -0.97% | 1.52% | 4.23% | 13.39% |
Profit Margin | -12.95% | 4.52% | 8.05% | 8.42% | 18.17% |
Free Cash Flow Margin | - | -4.27% | -4.15% | -12.31% | -19.07% |
EBITDA | -13.67 | 33.68 | 45.74 | 53.84 | 75.33 |
EBITDA Margin | -3.94% | 7.15% | 9.20% | 10.61% | 17.16% |
D&A For EBITDA | 38.24 | 38.24 | 38.2 | 32.35 | 16.53 |
EBIT | -51.91 | -4.56 | 7.54 | 21.49 | 58.8 |
EBIT Margin | -14.95% | -0.97% | 1.52% | 4.23% | 13.39% |
Effective Tax Rate | - | - | - | - | 15.15% |
Revenue as Reported | - | 470.79 | 497.29 | 507.38 | 438.99 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.